Preclinical News and Research

RSS

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

New 3D organoid model reveals a possible biological target for treating GEJ cancers

Researchers at Johns Hopkins Medicine say they have created a laboratory-grown three-dimensional "organoid" model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction (GEJ) — the point where the digestive system's food tube meets the stomach.

2 Dec 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

AXT Bring Novel Photoacoustic Imaging Technology to Australian Medical Researchers

AXT is pleased to announce a further expansion to their preclinical imaging portfolio with the addition of Luxonus

From AXT Pty Ltd 15 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

Potential therapeutic strategy for medulloblastoma relapse

Medulloblastoma, a kind of malignant brain tumor, can develop resistance to therapy, resulting in relapse. Uppsala University scientists found a protein that causes tumor cells to rest and become insensitive to radiation treatment.

1 Nov 2022

New tool advances potential means to deliver gene therapy

Researchers from Johns Hopkins Medicine claim to have successfully “slid” genetic instructions into a cell and produced essential proteins that were lacking from those cells using a cell’s normal process for creating proteins.

1 Nov 2022

Metabolite from pomegranate to boost immune cells that fight tumors

Researchers from the Georg-Speyer-Haus in Frankfurt am Main, Germany, and Goethe University Frankfurt have succeeded in developing a new strategy for the treatment of colorectal cancer as part of an interdisciplinary initiative of the LOEWE Center Frankfurt Cancer Institute (FCI).

28 Oct 2022

A more efficient way to deliver gene therapies to the CNS

For gene therapy, the blood-brain barrier (BBB) poses a formidable obstacle. The BBB, which is made up of cells that are closely packed together, prevents poisons and pathogens from accessing brain tissue while also blocking potential treatments for diseases that impact the CNS.

12 Oct 2022

A remarkable finding reorients attempts to cure liver disease

A long-running debate in gastroenterology has been settled by WEHI researchers who have shown that prevalent liver diseases are not caused by inflammatory cell death as previously believed.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 7 Oct 2022

Highly effective and safe Zika vaccine technology

Scientists from the University of California, Los Angeles (UCLA) have discovered a Zika vaccine technology that is very safe and effective in preclinical mouse models.

29 Sep 2022

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

A “stress test” with a previously unknown gene to revive the exhausted T cells

The task of battling cancer cells can fatigue T cells employed in immunotherapy treatments, or they could shut down once they penetrate tumors. Researchers at the Gladstone Institutes and UC San Francisco have strengthened the therapeutic cells’ resistance via a CRISPR-based edit on their genomes.

30 Aug 2022

Inventia Life Science Announces Partnership with PhenoVista Biosciences to Accelerate Preclinical Research with 3D Cell Models

Inventia Life Science, a leader in automated generation of complex 3D cell models, and PhenoVista Biosciences, a top provider of custom imaging-based phenotypic assay services, have entered into a partnership to deliver high-content cell-based assay services for drug discovery.

From Inventia Life Science 16 Aug 2022

Researchers discover key cells that control interaction in parts of the brain

A research group from MedUni Vienna’s Center for Brain Research has identified key cells that control data communication between parts of the brain.

18 Jul 2022

Researchers get funding to develop a vaccine against ALS disease

DZNE and Intravacc B.V., have received a grant from the European Union of € 2.5 million to further create a prototype ALS vaccine.

8 Jul 2022

Researchers target human protein to combat SARS-CoV-2 and other viruses

People are realizing now, more than two years into the COVID-19 disease outbreak, that the “new normal” will most likely involve practicing to coexist with SARS-CoV-2.

1 Jul 2022

Scientists discover proteins that may improve CAR-T cell therapy for solid tumor model

The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.

27 Jun 2022

Study shows how probiotic bacteria may lower the risk of ER+ breast cancer

A new study presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., suggests that probiotic bacteria may improve the anti-cancer actions of the breast cancer drug tamoxifen as well as other endocrine-targeted therapies, potentially lowering the risk of estrogen receptive positive (ER+) breast cancer.

13 Jun 2022